GLP-1 Microdosing Explained: Longevity, Brain Health & Cardiovascular Research

GLP-1 microdosing is emerging as a conversation in longevity medicine beyond weight loss. In this video, I explain the research on GLP-1 peptides, brain health, cardiovascular risk, inflammation, and healthy aging. We cover: • What “microdosing” GLP-1 actually means • How insulin signaling changes as we age • The connection between inflammation and aging • Research on cardiovascular outcomes in clinical trials • Brain health and neuroinflammation data • Liver and kidney findings in metabolic studies • What applies to obesity and metabolic disease — and what we can cautiously extrapolate to healthy aging populations • Why lifestyle foundations still matter most Most long-term outcome data comes from individuals with obesity or insulin resistance. In this discussion, we look at the biology, the clinical evidence, and the limitations — so you can think critically about GLP-1 peptides in the context of aging well. This video is for educational purposes only and is not medical advice. If you’re interested in science-based longevity, metabolic health, peptides, and aging research — subscribe and join the conversation. AgelessRx GLP-1 microdosing options: https://agelessrx.pxf.io/c/4539887/3435685/26644 0:00 Introduction to GLP-1 0:53 Microdosing explained 1:34 Insulin and metabolic aging 3:07 Inflammation and brain health 4:31 Cardiovascular health 6:08 Liver and kidney support 7:21 Body composition and fat 8:35 Skin and visible aging 9:45 Evidence and safety 11:43 Foundations and conclusion